Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients

Clinical Infectious Diseases

Volumn 33, Issue , 2001, Pages

  Preiksaitis, Jutta K ^a   Keay, Susan ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN;

CHROMOSOME ABERRATION; CONFERENCE PAPER; EPSTEIN BARR VIRUS; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT;

ANTIVIRAL AGENTS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 0034987887     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320903     Document Type: Article

References (104)

1. Epstein-Barr virus, immunodeficiency, and B-cell proliferation
2. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
3. Incidence and consequences of post-transplant lymphoproliferative disorders
4. Pretransplantation assessment of the risk of lymphoproliferative disorder
5. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of CMV disease
6. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation
7. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy
8. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
9. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression
10. Incidence of post-transplant malignancy among 674 solid-organ transplant recipients at a single center
11. Epstein-Barr virus infections in children after transplantation of the small intestine
12. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder
13. Preventing acute rejection, Epstein-Barr virus infection and posttransplant lymphoproliferative disorders after kidney transplantation: Use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol
14. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders
15. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
16. Lymphoproliferative disorders after organ transplantation in children
17. Post-transplant lymphoproliferative disorder
18. Basic virologic aspects of Epstein-Barr virus infection
19. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients
20. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx
21. Epstein-Barr virus infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
22. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders
23. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin
24. Epstein-Barr virus transmission via the donor organ in solid organ transplantation: Polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4
25. Epstein-Barr virus (EBV)-induced B cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
26. Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disorder
27. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation
28. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas
29. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease
30. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders
31. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses and the risk of post-transplant lymphoproliferative disorder
32. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
33. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder
34. Cytologic findings in posttransplant lymphoproliferative disease
35. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop
36. Posttransplant lymphoproliferative disorder in liver allograft biopsies: A comparison of three methods for the demonstration of Epstein-Barr virus
37. Epstein-Barr virus detection in sequential biopsies from patients with a posttransplant lymphoproliferative disorder
38. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus
39. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder
40. Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy
41. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation
42. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation
43. Early identification of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease
44. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease
45. Epstein-Barr virus PCR correlated with viral histology and serology in pediatric liver transplant patients
46. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
47. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
48. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR
49. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders
50. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease
51. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
52. Post-transplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center
53. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: Primary presentation in the allograft
54. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation
55. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder
56. Epstein-Barr virus detection in sequential biopsies from patients with a posttransplant lymphoproliferative disorder
57. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy
58. Aggressive treatment for postcardiac transplant lymphoproliferation
59. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases
60. Lymphoproliferative disorder early after cardiac transplantation
61. Immunosuppression: A contributory factor in lymphoma formation
62. Epstein-Barr virus polymerase chain reaction and serology in pediatric post-transplant lymphoproliferative disorder: Three-year experience
63. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR
64. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients
65. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
66. Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants
67. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir
68. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression
69. Effects of interferon-alpha therapy on immune parameters in immune thrombocytopenic purpura
70. Interferon-alpha and its effects on post-transplant lymphoproliferative disorders
71. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation
72. Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder
73. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma-globulin
74. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin
75. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy
76. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients: Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections
77. Interferon-α-induced acute renal allograft rejection
78. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
79. Anti-B cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
80. Anti-B cell antibodies for the treatment of monoclonal Epstein-Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation
81. Therapy for transplant-related lymphoproliferative diseases
82. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant lymphoproliferative disorder: A retrospective analysis on 32 patients
83. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
84. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
85. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
86. Central nervous system lymphomas in organ allograft recipients
87. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody
88. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation
89. Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation
90. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy
91. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis
92. Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease
93. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
94. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
95. Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease
96. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and negative lymphoproliferative disorders arising in organ transplant recipients
97. Biological effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
98. Renal transplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease
99. Posttransplant lymphoproliferative disease of the liver successfully treated by retransplantation
100. Retransplantation after post-transplant lymphoproliferative disease
101. Posttransplant lymphoproliferative disease in pediatric liver transplantation: Interplay between primary Epstein-Barr virus infection and immunosuppression